What is HC Wainwright’s Estimate for HOWL Q1 Earnings?

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings estimates for Werewolf Therapeutics in a research note issued on Friday, November 8th. HC Wainwright analyst A. Maldonado forecasts that the company will earn ($0.38) per share for the quarter. The consensus estimate for Werewolf Therapeutics’ current full-year earnings is ($1.64) per share. HC Wainwright also issued estimates for Werewolf Therapeutics’ Q2 2025 earnings at ($0.40) EPS, Q3 2025 earnings at ($0.42) EPS and Q4 2025 earnings at ($0.43) EPS.

Werewolf Therapeutics Trading Down 2.3 %

Shares of NASDAQ:HOWL opened at $2.15 on Monday. The stock has a market cap of $93.96 million, a PE ratio of -1.41 and a beta of 0.41. The company has a quick ratio of 12.13, a current ratio of 12.13 and a debt-to-equity ratio of 0.24. Werewolf Therapeutics has a 12-month low of $1.66 and a 12-month high of $8.19. The business has a 50 day moving average of $2.27 and a 200-day moving average of $2.93.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HOWL. American Century Companies Inc. grew its stake in shares of Werewolf Therapeutics by 50.7% in the second quarter. American Century Companies Inc. now owns 37,634 shares of the company’s stock valued at $92,000 after acquiring an additional 12,656 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Werewolf Therapeutics during the 3rd quarter worth approximately $29,000. Point72 DIFC Ltd bought a new position in shares of Werewolf Therapeutics during the second quarter worth approximately $34,000. Rhumbline Advisers acquired a new stake in shares of Werewolf Therapeutics in the second quarter valued at approximately $79,000. Finally, Acadian Asset Management LLC boosted its stake in shares of Werewolf Therapeutics by 22.8% in the second quarter. Acadian Asset Management LLC now owns 212,296 shares of the company’s stock valued at $516,000 after buying an additional 39,413 shares during the period. 64.84% of the stock is owned by institutional investors and hedge funds.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.